<SEC-DOCUMENT>0001683168-23-005536.txt : 20230810
<SEC-HEADER>0001683168-23-005536.hdr.sgml : 20230810
<ACCEPTANCE-DATETIME>20230810211444
ACCESSION NUMBER:		0001683168-23-005536
CONFORMED SUBMISSION TYPE:	4/A
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20230505
FILED AS OF DATE:		20230810
DATE AS OF CHANGE:		20230810

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Cockroft Bettina M.
		CENTRAL INDEX KEY:			0001900452

	FILING VALUES:
		FORM TYPE:		4/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39126
		FILM NUMBER:		231161318

	MAIL ADDRESS:	
		STREET 1:		C/O ANNEXON, INC.
		STREET 2:		180 KIMBALL WAY, SUITE 200
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CNS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001729427
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				822318545
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
		BUSINESS PHONE:		1-800-946-9185

	MAIL ADDRESS:	
		STREET 1:		2100 WEST LOOP SOUTH
		STREET 2:		SUITE 900
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77027
</SEC-HEADER>
<DOCUMENT>
<TYPE>4/A
<SEQUENCE>1
<FILENAME>ownership.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4/A</documentType>

    <periodOfReport>2023-05-05</periodOfReport>

    <dateOfOriginalSubmission>2023-05-09</dateOfOriginalSubmission>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001729427</issuerCik>
        <issuerName>CNS Pharmaceuticals, Inc.</issuerName>
        <issuerTradingSymbol>CNSP</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001900452</rptOwnerCik>
            <rptOwnerName>Cockroft Bettina M.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O CNS PHARMACEUTICALS, INC</rptOwnerStreet1>
            <rptOwnerStreet2>100 WEST LOOP SOUTH, SUITE 900</rptOwnerStreet2>
            <rptOwnerCity>HOUSTON</rptOwnerCity>
            <rptOwnerState>TX</rptOwnerState>
            <rptOwnerZipCode>77027</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Option to purchase common stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.67</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2023-05-05</value>
            </transactionDate>
            <deemedExecutionDate></deemedExecutionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionTimeliness></transactionTimeliness>
            <transactionAmounts>
                <transactionShares>
                    <value>2099</value>
                </transactionShares>
                <transactionPricePerShare>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2033-05-05</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>2099</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>2099</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The options set forth in this table vest in 36 equal monthly installments succeeding the issuance date, or May 5, 2023, subject to the grantee's continued service on the Company's Board of Directors on each vesting date.</footnote>
        <footnote id="F2">The options were issued in connection with the reporting person's Board of Director services to the Company.</footnote>
    </footnotes>

    <remarks>This amendment is being filed to correct the number of shares underlying the options set forth in Table II from 8,300 shares of common stock to 2,099 shares of common stock, and to correct the expiration date of the options from May 5, 2023 to May 5, 2033.</remarks>

    <ownerSignature>
        <signatureName>/s/ Christopher Downs, Attorney-in-fact</signatureName>
        <signatureDate>2023-08-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
